Combining imatinib and AIC-47 treatment, strengthened inhibition of glycolysis, and synergistic cytotoxicity was observed in leukemia cell line K562 and KCL-22 and in human BCR/ABL-positive CML cells [183]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.